Navigation Links
VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
Date:8/4/2009

MOUNTAIN VIEW, Calif., Aug. 4 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that Timothy Morris, chief financial officer, will present an overview of the company at the Canaccord Adams 29th Annual Global Growth Conference in Boston.

The VIVUS presentation will take place at the Intercontinental Hotel on Thursday, August 13, 2009 at 8:30 a.m. ET. A live webcast and 30-day archive of the presentation will be available at http://www.wsw.com/webcast/canaccord/vvus or http://www.vivus.com.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead investigational product in clinical development, Qnexa(TM), is expected to complete Phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in Phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in Phase 3 development with avanafil, its PDE5 inhibitor drug candidate, and in Phase 2 development of Luramist(TM), its drug candidate for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

<
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. VIVUS to Present at the Needham and Company Life Sciences Conference
2. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
3. VIVUS Reports First Quarter 2009 Financial Results and Highlights
4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer
6. Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
7. Stemline Therapeutics CEO to Present at IBCs New Frontiers in Cancer Drug Development Conference
8. PDL BioPharma to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
9. Patent Awarded for a New X-ray Imaging Technology with Capability Unrealized with Present Day Radiological Modalities
10. NovaBay(R) Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
11. Histogen Hair Regrowth Clinical Trial Presented at ISHRS Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... of last week RENU 28, the world's first and only ... purchase in Australia and New Zealand, and the response has ... if you think about the definition of aging, it's really ... your body. If you think about the definition of anti-aging, ... RENU 28 does is it works with these tiny little ...
(Date:8/20/2014)... 2014 Neurotrope, Inc. (OTCQB: NTRP) today ... to provide an update on Company activities. Access ... numbers:(888) 505-4369 (U.S. and Canada) or (719) 325-2315 ... , under "Investor Relations"The teleconference replay will be ... 2, 2014 at (888) 203-1112 (U.S. and ...
(Date:8/20/2014)... August 20, 2014 Not long ago, ... studies should be performed late in the development cycle ... But current regulatory trends suggest that, like many things ... rise. In recent years, multiple drug sponsors have been ... address specific questions during phase I/II. It’s not only ...
(Date:8/19/2014)... Piscataway, NJ (PRWEB) August 20, 2014 ... engineering and regenerative medicine is an inadequate vascular ... engineered constructs and decellularized tissues is critical for ... Researchers have attempted to mitigate deficiencies in vascularization ... including adding scaffold bioactivity, optimizing scaffold design and ...
Breaking Biology Technology:RENU 28 Skin Care Now Available in Australia and New Zealand 2Neurotrope To Host Conference Call 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2
... May 12 Aton Pharma, Inc., a global,specialty ... a,distribution agreement with Meizler Biopharma S/A to commercialize,CUPRIMINE(R) ... in,Brazil, and Meizler is working to obtain regulatory ... medically essential products, and Aton is,committed to making ...
... Poised to Impact Lung Cancer Care, ST. ... medical,device start-up company, has secured $4.75M in venture ... IG4 delivery system for minimally,invasive biopsy and ablation ... and was joined by Advantage Capital Partners and ...
... (NYSE:,CVD) today announced that it will present at the ... 2008 at 10:30 am ET. Investors may,access a live ... order to,register and download any necessary software, please log ... New Jersey, is one of the,world,s largest and most ...
Cached Biology Technology:Aton Pharma Announces Distribution Partnership in Brazil 2Veran Medical Technologies Secures $4.75M in First Institutional Funding 2
(Date:8/19/2014)... Research and Network-Level Science, , Imagine if we had ... ecosystems was responding to global changes in real time. ... coupled multiple decades of information about ecological responses to ... dozens of different ecosystem types. , In fact, ... (LTER) Network, which will soon celebrate its 35th anniversary. ...
(Date:8/19/2014)... leprosy and tuberculosis live side-by-side. Worldwide there are ... with nearly all of them occurring where tuberculosis ... Calmette-Guerin, or BCG, provides only partial protection against ... vaccine is needed to combat both diseases. UCLA-led ... both diseases., In a study published in the ...
(Date:8/19/2014)... devised a new implantable tissue scaffold coated with bone ... weeks. When applied to bone injuries or defects, this ... bone that looks and behaves just like the original ... a dramatic improvement over the current standard for treating ... of the patient,s body a painful process that ...
Breaking Biology News(10 mins):This week from AGU: Long-term ecological research, predicting cholera outbreaks 2New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2Engineering new bone growth 2Engineering new bone growth 3
... within weeks after a person is infected with the HIV ... Center and the Bernard-Nocht Institute appearing in the international open-access ... mostly found in the digestive tract, tend not to return ... In recent years, HIV infection has been shown to deplete ...
... Oct. 2 tells a tale of "genome archaeology" by ... of maize and rice. Their resulting insights into plant ... genetically modified organism (GMO) controversy. , "Our findings elucidate ... much like modern biotechnologists do. Now we must reassess ...
... the December issue of the journal Cell Metabolism, published ... which the mammary glands of mammals meet the incredible ... of breast development undoubtedly affect breast cancer, the findings ... researchers found that one of three “isoforms?of the gene ...
Cached Biology News:Early HIV treatment fails to restore memory T cells 2Genome archaeology illuminates the genetic engineering debate 2How mammals fuel milk production may have implications for cancer 2How mammals fuel milk production may have implications for cancer 3
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient vir...
...
Request Info...
... and miRNA Isolation Traditional mRNA isolation ... and can result in the loss of ... miRNA Isolation Kit purifies all RNA species ... Through an enrichment procedure included in the ...
Biology Products: